Larimar Therapeutics, Inc.
Public company- Headquarters
- BALA CYNWYD, Pennsylvania
- Ticker
- LRMR
- CIK
- 0001374690
WARN notices since 2024
0
None on record
Workers affected since 2024
0
Across 0 notices
Executive changes, last 12 months
1
1 appointment, 0 departures
Last event
Sep 29, 2026
Executive appointmentCOO appointed: John B. Harlow, Jr.
Workers affected over time
Cumulative workers in WARN notices since 2024
Not enough notices to chart yet.
Leadership
| Role and person | Since | Change |
|---|---|---|
| COOJohn B. Harlow, Jr. | Sep 29, 2026 | Appointed |
Related companies
Same industry and state, with recent events.
- MADRIGAL PHARMACEUTICALS, INC.
Class II director appointed: John C. Reed, M.D., Ph.D.
- BRISTOL MYERS SQUIBB CO
WARN notice: Princeton, NJ
- JOHNSON & JOHNSON
WARN notice: New Brunswick, NJ
- Merck & Co., Inc.
WARN notice: Rahway, NJ
- Executive appointment
COO appointed: John B. Harlow, Jr.
John B. Harlow, Jr. was named President and Chief Operating Officer of Larimar Therapeutics, Inc., effective September 29, 2026. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Sep 29, 2026Role: President and Chief Operating Officer
Only one public record so far. We add events as soon as a new filing lands; watch Larimar Therapeutics, Inc. to get them in your digest.
Last verified Nov 8, 2026